CALIXAR, the French Biotech company specialized in the isolation of native membrane protein targets, will present its innovative approach during the upcoming 4th GPCR Symposium in Toulouse (France) in November 2015. Dr. Sébastien IGONET (R&D Project Leader in Biochemistry) will describe some examples of highly druggable targets that were produced in their most native state without any single mutation, truncation or fusion and that could exhibit striking thermo-stability increase and homogeneity improvement, while keeping their functional features. A case study of functional and native A2A solubilized and purified for antibody development purposes and crystallization will highlight our approach.
The GDR3545 on “G Protein-coupled Receptors : from physiology to drugs (RCPG-Physio-Med)” was created in 2012 by the CNRS. The GDR3545 is affiliated to the “Institut des sciences biologiques” (INSB) and the “section 28” “Pharmacology, bio-engineering, imaging, biotechnology” of the Comité National de la Recherche Scientifique. The GDR3545 is composed of approximately 600 members working in 57 research teams from different research organizations (CNRS, Inserm, CEA, INRA, etc.).
DATES : November 04-06 2015
MORE INFO : GRD3545